Speakers

Expand/Collapse

Madhu Lal-Nag
Program Lead, Research Governance Council
FDA

Day One

Wednesday | September 22, 2021

10:30 am | Panel Discussion: Enhancing 3D Models Adoption in Preclinical & Clinical Studies

9:00 am | KEYNOTE: FDA’s Update on Packaging Your 3D Model Data for IND Filing

Matthew Wagoner
Director of Investigative Toxicology
Takeda

Matt Wagoner leads the Global Investigatory Toxicology team at Takeda Pharmaceuticals, where their team applies complex in vitro models and in silico approaches as predictive and mechanistic tools to help make safer medicines.  Before Takeda, Matt led the mRNA safety strategy for AstraZeneca Pharmaceuticals, and worked to develop and deploy in vitro and in vivo models in support of oncology and cardiovascular drug discovery projects. In the academic arena, Matt co-taught a drug discovery course at Simmons College in Boston.  He received his PhD in Molecular and Cellular Pharmacology from the University of Wisconsin-Madison and bachelors in biochemistry from the University of Illinois Urbana Champaign. In lieu of hobbies, Matt has four kids and a debilitating addiction to home improvement projects.

Day Two

Thursday | September 23, 2021

11:30 am | Surviving the Technology Hype Cycle: Where MPS Are Having an Impact Today & Where They Are Needed Next

Don Ingber
Director
Wyss Institute at Harvard

Day Two

Thursday | September 23, 2021

1:30 pm | Body on a Chip: Reimagining Drug Testing

Steve Titus
Scientific Leader Functional Genomics
GlaxoSmithKline

Steve has spent more than 25 years’ of research experience spanning Academia and Industry. Within the past decade, he shifted his focus to High Content Imaging and Analysis. Steve holds an MS degree in Genetics from UW-Madison where he focused on the neurogenetics of Drosophila melanogaster. Steve has spent almost 10 years at the NIH Center for Advancing Translational Sciences as a High Throughput Assay Biologist. In 2017, Steve moved to GSK where he is currently working in the High Throughput Biology and Imaging group as a Scientific Leader. Steve has co-authored over 40 peer reviewed publications and holds several patent inventions.

Day Two

Thursday | September 23, 2021

5:00 pm | Let’s Take a Closer Look through a Powerful Lens – Real Time Imaging

Jason Ekert
Senior Director & Head of Complex In Vitro Models
GlaxoSmithKline

Dr. Jason Ekert is head of the Complex In Vitro Models (CIVM) group at GlaxoSmithKline. He leads an integrated enterprise strategy for R&D applications of complex human-relevant and translatable complex in vitro models (eg Spheroids, Organoids, Microphysiological systems and bioprinting). He’s the vice-chair for the IQ-MPS affiliate. Dr Ekert received his PhD in Medical Science from Adelaide University in Australia. He performed post-doctoral training at the University of California, Davis and Coriell Institute for Medical Research. Before coming to GlaxoSmithKline Dr Ekert worked for 11 years at Janssen BioThereapeutics in early biotherapeutic drug discovery in target discovery, drug validation and mechanism of action studies applying complex cell-based assays across multiple therapeutic areas.  

Day One

Wednesday | September 22, 2021

10:30 am | Panel Discussion: Enhancing 3D Models Adoption in Preclinical & Clinical Studies

9:30 am | IQ MPS Affiliate Update: A Pharmaceutical Industry Perspective on Advancing MPS Adoption in Drug Discovery

Roger Kamm
Professor
MIT

Kamm is the Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering at MIT, where he has served on the faculty since 1978. Kamm has long been instrumental in developing research activities at the interface of biology and mechanics, formerly in cell and molecular mechanics, and now in engineered living systems.  Current interests are in developing models of healthy and diseased organ function using microfluidic technologies, with a focus on vascularization.  Kamm has fostered biomechanics as Chair of the US National Committee on Biomechanics (2006-2009) and of the World Council on Biomechanics (2006-2010).  He currently directs the NSF Science and Technology Center on Emergent Behaviors of Integrated Cellular Systems. He has received numerous awards including the ASME Lissner Medal (2010) and the ESB Huiskes Medal (2015), both for lifetime achievements, and is the inaugural recipient of the ASME Nerem Medal for mentoring and education. In 2020 he received the Shu Chien Award from the Cell and Molecular Engineering Division of BMES.  He was elected to the National Academy of Medicine in 2010. Kamm is co-founder of two companies, Cardiovascular Technologies, and AIM Biotech, a manufacturer of microfluidic systems for 3D culture.

TRACK B- DAY ONE MORNING

12:30 pm | A Multi-Functional MPS Platform: Applications to Modeling the Blood-Brain Barrier & Subcutaneous Delivery

Danilo Tagle
Associate Director for Special Initiatives
NIH/ NCATS

Day One

Wednesday | September 22, 2021

10:30 am | Panel Discussion: Enhancing 3D Models Adoption in Preclinical & Clinical Studies

10:00 am | The NIH Microphysiological Systems Program

Matthew Lech
Senior Principal Scientist
Pfizer

Nicholas Geisse
Chief Scientific Officer
Curi Bio

TRACK B- DAY ONE MORNING

1:00 pm | Engineered 3D Heart Tissues as Models of Disease & Discovery

Shamin Li
Senior Scientist
Roche Diagnostics

TRACK A - DAY ONE MORNING

12:00 pm | Utilizing Primary Tumor Explants for the Assessment of the Activity of Cancer Immunotherapy Drugs

Kimberly Homan
Director - Complex In Vitro System Group
Genentech

TRACK B - DAY ONE AFTERNOON

3:00 pm | Leveraging Various In Vitro Kidney Models to Predict Drug Safety & Mechanisms of Action

Phillip Hewitt
Global Head of Early Investigative Toxicology
Merck KGaA

TRACK B- DAY ONE MORNING

12:00 pm | Mechanistic Understanding of Clinical Drug Induced Liver Injury (DILI): What Can & Can’t be Done Using 3D Liver Models

Stephen Kasper
Exploratory Science Center Scientist
Merck & Co.

I earned my B.S. in Biochemistry and Molecular Biology and Ph.D. in Nanoscale Engineering at the University at Albany, State University of New York, where I developed novel models of pathogenic biofilm formation and used these for phenotypic screens of anti-biofilm compounds and target elucidation. I was a co-founder of a biotech start-up, Empire Biotechnologies Inc., which was focused on the development of protein-based therapeutics for gastrointestinal conditions. I joined the Merck Exploratory Science Center in 2017 and since have been focused on research at the intersection of bioengineering and the human microbiome in the context of oncology, infectious diseases, and cardiometabolic disease.

Day Two

Thursday | September 23, 2021

2:30 pm | Novel Host-Microbe In Vitro Model for Colorectal Cancer-Associated Anaerobic Bacteria & Microenvironment

Matthias Von Herrath
Vice President & Senior Medical Officer
Novo Nordisk

TRACK B - DAY ONE AFTERNOON

3:30 pm | Re-Evaluating Immune Modulation for Stem-Cell Derived Therapies Using 3D In Vitro Tissue Models of Immune Attack

BanuPriya Sridharan
Investigator Organoids & Cell Biology
GSK

Day Two

Thursday | September 23, 2021

4:00 pm | Complex 3D Microfluidic Disease Model with Multiple Cell Types

Serah Kang
Scientist
Genentech

TRACK B - DAY ONE AFTERNOON

2:30 pm | Using Human iPSC-Derived Cardiac Organoids & Bioinformatics to Predict COVID-19-Associated Patient Pathology

Ruitao Su
Postdoctoral Associate
University of Minnesota

TRACK A - DAY ONE MORNING

1:00 pm | 3D Printed Microfluidics with Applications in Drug Screening & Oncology Research

Trivia Frazier
President & Chief Executive Officer
Obatala Sciences

Dr. Frazier received her Ph.D. from Tulane University School of Medicine, graduating from the Biomedical Sciences Program in 2012. Her dissertation training projects involved the use of cryopreserved adult mesenchymal stem cells derived from adipose tissue for clinical use in tissue reconstruction and regenerative medicine applications. She has held tenure-track faculty positions at Delgado Community College and served as Program Chair in the Chemistry and Chemical Technology Department at Dillard University.

Day Two

Thursday | September 23, 2021

10:00 am | Fat-on-a-Chip for Drug Discovery & Preclinical Studies

Prathap Kumar Mahalingaiah
Senior Scientist
Abbvie

Day Two

Thursday | September 23, 2021

9:30 am | Application of MPS Models in Investigative Toxicology: Current Challenges & Learnings

Madhuri Dey
Doctoral Candidate
Pennsylvania State University

Madhuri Dey is a senior Ph.D. candidate at the Department of Chemistry and a member of the Huck Institutes of the Life Sciences at Penn State University. Her work focuses on developing in vitro tumor models for immunotherapy. Employing state-of-the-art 3D bioprinting technology, she also studies tumor angiogenesis and cancer invasion in static as well as dynamic culture systems. She has received a Master’s Degree in Chemistry from the University of Hyderabad and a Bachelor’s degree in Chemistry from St. Xavier’s College, Kolkata, India.

TRACK A - DAY ONE AFTERNOON

2:30 pm | Bioprinting the Tumor Microenvironment

Jos Joore
Chief Executive Officer
MIMETAS

Jos Joore is a biotech entrepreneur with over 18 years of executive level bio-business experience and 8 years in biosciences. As CEO and co-founder of MIMETAS, Jos closed deals with most top-10 pharma companies, secured series A and B investment rounds and enabled mass production & global marketing of OrganoPlates. Previously, he has held managerial positions within biotech companies Pepscan, Skyline Diagnostics, Kreatech and Westburg. Jos holds a masters degree in Biology, a Ph.D. in Developmental Biology and a cum laude masters degree in Business Marketing.

Day Two

Thursday | September 23, 2021

10:45 am | High-throughput Organ-on-a-Chip Platform for Disease Modeling & Therapeutic Screening

Kristin Fabre
Chief Scientist; Assistant Professor, Translational Research Institute for Space Health
Baylor College

Dr. Fabre joined TRISH December 2018 as a Senior Innovation Scientist, and was promoted to Chief Scientist May 2020.  She leads the TRISH Translational Program, which is tasked to invest in high-risk, high-reward research and technology for space exploration.  She works with various stakeholders including NASA, industry and academia to adopt and implement outcomes from TRISH-funded project deliverables. Before joining TRISH, Dr. Fabre was the Microphysiological Systems (MPS) Lead at AstraZeneca and was part of the MPS Center of Excellence, Drug Safety and Metabolism.  Prior to joining AZ in 2016, she was the Scientific Program Manager for the Microphysiological Systems (or Organs-on-Chips) Initiative at NIH National Center for Advancing Translational Sciences (NCATS). Dr. Fabre received her BS in Biology from the University of Wyoming, followed by her MS and PhD from Colorado State University in Cell and Molecular Biology.  Prior to joining NCATS, she was at the NIH National Cancer Institute as a postdoctoral fellow in the Radiation Biology Branch.  During her time at the NCI, Dr. Fabre was highly involved with training programs and was Chair of the NCI Fellows and Young Investigators Steering Committee and created the NCI Fellows Outreach Committee.

Day Two

Thursday | September 23, 2021

2:00 pm | Chips on the Moon

Jeroen Pouwels
Research Coordinator
University of Helsinki

Prof. Jeroen Pouwels works as research coordinator in the Klefström research group at the Faculty of Medicine at the University of Helsinki. He is founder and research coordinator of the Cancer IO consortium, a large (10 M€ funding, 30+ partners) public-private consortium focusing on immuno-oncology. In addition, he has obtained independent research funding to develop patient-derived tumor explant cultures as a predictive preclinical model for breast cancer and to identify treatments that sensitize breast cancer to immunotherapies. Lastly, Jeroen is involved in the preparation of an investigator-initiated phase I clinical trial in metastatic breast cancer and in spinning out a diagnostic company that utilizes tumour explant cultures.

TRACK A - DAY ONE MORNING

12:30 pm | Patient-Derived Explant Cultures (PDECs) as a Model System for Oncology Studies

Timothy Spicer
Senior Director- Molecular Medicine & Scientific
The Scripps Research Institute

The focus of our research involves enabling technologies for High Throughput Screening (HTS) of any target of unmet therapeutic need. Our facility supports scientist and faculty locally as well as those in the US and throughout the world. We do this by implementing their biological applications into high density plates for HTS. The breadth of biology we deal with is virtually unlimited due to the diversity of skill sets of the scientist and engineers within our group as well as the expanded capability of the readers associated to our system. We operate a fully automated 1536 well compatible platform and perform HTS on large compound libraries such as the Scripps Drug Discovery Library (645K) or small focused collections (FDA approved drugs). We have expertise in microfluidics, low nanoliter volume liquid handling, ultra-sensitive plate reader technologies and informatics set-up to handle large volume data sets. Key components are high-content readers, imaging detectors such as the ViewLux and FLIPR Tetra, as well as pintool and acoustic transfer devices. Through collaborative efforts we have successfully translated multiple small molecules into the clinics. We are open to any pharmacology desired (agonist, PAMs, NAMs, inverse agonist, etc.) vs. kinases, GPCR, NHRs, proteases, phenotypic assays, etc. which can be applied to any therapeutic area; i.e. CNS, infectious diseases, cardiovascular, oncology, metabolic diseases. In addition, we are currently funded (R33CA206949) to develop 3D spheroid based uHTS assays for the purpose of testing molecules in a more phenotypically relevant format to cancer biology.

TRACK A - DAY ONE AFTERNOON

3:00 pm | Case Study: Using Patient Derived 3D Models to Test Combinatorial Therapy Approaches for the Treatment of Glioblastoma (GBM)

Lisa Wagar
Assistant Professor
University of California Irvine

Day One

Wednesday | September 22, 2021

4:40 pm | Deciphering Immune Responses to Viruses & Vaccines Using Human Tonsil Organoids

Annie Moisan
Bioengineering Program Director
Wellcome Leap

As the HOPE bioengineering Program Director at Wellcome Leap, Annie leads multidisciplinary teams aiming to deliver scientific breakthroughs in human health by leveraging on engineered human tissues and organs. Prior to joining Wellcome Leap in 2020, Annie had worked in the pharmaceutical industry for nearly 10 years, where she developed and applied advanced human cell models for preclinical drug profiling and mechanistic understanding of drug toxicity. As a Group Leader in Investigative Safety at the Roche Innovation Center Basel, Annie drove the strategic implementation of human translational models in support of emerging therapeutic modalities in collaboration with academic institutions, biotech partners, and regulatory advocates. Annie trained as a postdoctoral fellow in cancer stem cell biology at Harvard Medical School from 2007 to 2011 and earned her Ph.D. in cell biology from University of Sherbrooke, Canada.

Day One

Wednesday | September 22, 2021

10:30 am | Panel Discussion: Enhancing 3D Models Adoption in Preclinical & Clinical Studies

Day Two

Thursday | September 23, 2021

9:00 am | Human Organs, Physiology & Engineering (HOPE) for Closing the Preclinical Gap

Suwan N. Jayasinghe
Professor of Bioengineering
UCL

Professor Jayasinghe leads the work of the BioPhysics Group in the Department of Mechanical Engineering at University College London. Jayasinghe has pioneered many works which have been internationally recognised through articles written about these in leading international society periodicals (American Chemical Societies – Chemical Engineering and News, American Institute of Physics Society’s – Physics Today to many others) and has been featured on international news media such as on the BBC, Associated Press, Bloomberg to Reuters to name a few. Jayasinghe has demonstrated the ability to print multi-material three-dimensional architectures without the use of supports, namely overhangs, to the ability to create 3D porous architectures. This work was awarded the Leonardo Da Vinci Gold Medal and the De Montfort Medal both presented to him at the Houses of Parliament in the United Kingdom. Subsequent he has pioneered and coined bio-platforms well-known as bio-electrosprays and cells electrospinning. These bio-platforms are the only technologies having the potential to directly handle multiple living cells in many permutations and combination to whole organisms for the controlled deposition and formation of three-dimensional functional tissues. These discoveries were recognised by the German Aerosol Society’s (The "Gesellschaft für Aerosolforschung e.V." (GAeF),  prestigious award The Smoluchowski Award and The Institute of Materials, Minerals and Mining (IOM3), through the Professor Sir George Beilby FRS Medal and Price. At present these discoveries are being adopted in the clinic for tissue repair, replacement to rejuvenation, with particular focus on tissue regeneration in cases of bed soars to those demanding wound healing for venous diabetic ulcers.

Day Two

Thursday | September 23, 2021

4:30 pm | Pioneering Bio-Platforms to Directly Handle Multiple Living Cells

Thomas Hartung
Chair for Evidencebased Toxicology & Director CAAT
John Hopkins Bloomberg School of Public Health

Day Two

Thursday | September 23, 2021

10:15 am | From Microphysiological to Micropathophysiological Systems